Moderate ResearchLongevity

Ovagen

EDL

EDL Tripeptide | Liver & GI Bioregulator

Half-life

Not established

Chain length

3 amino acids

Reference frequency

Daily for 10-20 days per cycle

Research overview

DoseGear research brief

Ovagen is a Khavinson bioregulator tripeptide (EDL) with primary effects on the liver and gastrointestinal tract. Developed by Dr. Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, it reduces long-term liver fibrosis and protects the GI mucosal layer from antibiotics, environmental toxins, and chemotherapy. Like other bioregulators, Ovagen crosses cell and nuclear membranes to directly regulate DNA transcription patterns with tissue-specific effects.

Mechanism of action

Ovagen works through epigenetic regulation by crossing cell and nuclear membranes to directly regulate DNA structure and transcription patterns. It is transported into cells via POT family transporters (PEPT1, PEPT2) that specifically handle di- and tripeptides, explaining its precise tissue targeting. The peptide has tissue-specific effects on liver and GI tract, reducing fibrosis and protecting mucosal integrity.

Compound background

Development & research timeline

Study windows describe what researchers measured, not when an individual should expect a result.

Origin & development

Short peptide associated with Khavinson liver and bioregulator research.

What it is researched for

Experimental hepatic tissue regulation through proposed gene-expression and protein-synthesis effects.

Research observation window

Not reported in the reviewed compound-specific evidence.

Reference data

Lyophilized vial injectable protocols

Not personalized dosing instructions

Only injectable vial references are shown. Nasal, topical, and unsupported non-vial schedules are excluded.

Research context	Amount	Frequency	Route
Chart reference	10 mcg	Daily · See source guide	Injectable · 20 mg lyophilized vial + 2 mL BAC Water

Reference cycle

10-20 days

Reference storage

Capsules at room temperature; reconstituted injectable at 2-8°C refrigerated

Safety context

Reported side effects

Generally well-tolerated
Minimal side effects reported

Contraindications & cautions

Active liver emergencies (seek medical care)
Known hypersensitivity
Pregnancy or breastfeeding

Scientific references

01
Khavinson Peptide Bioregulators Overview
Scientific citationKhavinson Peptide Bioregulators Overview. Advances in Gerontology (2020).
02
POT Family Transporters and Peptide Bioregulators
Scientific citationPOT Family Transporters and Peptide Bioregulators. Drug Metabolism Reviews (2018).
03
Peptide Bioregulators and Liver Fibrosis
Scientific citationPeptide Bioregulators and Liver Fibrosis. Experimental Gerontology (2019).

This DoseGear profile combines published scientific literature with lyophilized-vial protocol references. Citations are provided for independent review.

Related research profiles

Longevity